Arrowhead Research Corporation
 
Insert Therapeutics, Inc. Unidym, Inc. Tego BioSciences, Inc. Aonex Technologies, Inc. Calando Pharmaceuticals, Inc.

Subsidiary Companies

Arrowhead Research Corporation forms or acquires subsidiary companies pursuing product and technology development in nanotechnology. Arrowhead maintains a majority interest in its subsidiaries and provides financial, administrative, corporate and strategic resources. This structure is designed to enable each management and technical team at the subsidiary level to focus on developing specific technologies for specific markets.

The company has the following majority-owned subsidiaries:

Aonex Technologies, Inc. is commercializing a proprietary process for fabricating semiconductor nanomaterials to help device manufacturers reduce costs and improve performance.

Insert Therapeutics, Inc. has designed patented cyclodextrin-containing polymer delivery systems that combine with small-molecule drugs and nucleic acids to significantly improve their solubility, stability, pharmacokinetics and targeting for enhanced safety and efficacy.

Calando Pharmaceuticals, Inc. employs its proprietary nanotechnology exclusively on therapeutic use of RNAi (RNA interference), a technique to “silence” the expression of genes that cause diseases.  Calando’s self-assembling nanoparticles, comprised of Calando’s proprietary polymer delivery system and in RNAi therapeutic, are designed for intravenous injection and have shown exemplary results in small-scale animal studies.

Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners.

Tego Biosciences Corporation is developing new therapeutics and other protective products based on the antioxidant properties of modified fullerenes.